Nuvalent (NASDAQ:NUVL) Lowered to “Hold” Rating by Robert W. Baird

Robert W. Baird cut shares of Nuvalent (NASDAQ:NUVL) from a strong-buy rating to a hold rating in a report released on Tuesday morning,Zacks.com reports.

Several other equities analysts have also recently weighed in on the company. Barclays reaffirmed an “equal weight” rating and issued a $124.00 price objective (down from $152.00) on shares of Nuvalent in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvalent in a report on Tuesday, April 21st. Guggenheim cut Nuvalent from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $151.00 to $124.00 in a report on Wednesday. Raymond James Financial cut Nuvalent from an “outperform” rating to a “market perform” rating in a report on Tuesday. Finally, Lifesci Capital cut Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 price target for the company. in a report on Tuesday. Five investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $131.15.

Nuvalent Price Performance

Shares of NASDAQ NUVL opened at $123.35 on Tuesday. The stock has a market capitalization of $9.74 billion, a PE ratio of -20.35 and a beta of 1.15. The business has a fifty day moving average price of $103.44 and a two-hundred day moving average price of $103.19. Nuvalent has a fifty-two week low of $71.13 and a fifty-two week high of $123.62.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the previous year, the business earned ($1.18) earnings per share. On average, equities analysts expect that Nuvalent will post -5.74 EPS for the current year.

Insider Transactions at Nuvalent

In other Nuvalent news, insider Henry E. Pelish sold 3,093 shares of the company’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $104.48, for a total value of $323,156.64. Following the completion of the transaction, the insider owned 65,604 shares of the company’s stock, valued at $6,854,305.92. This represents a 4.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO James Richard Porter sold 30,000 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $88.53, for a total value of $2,655,900.00. Following the completion of the transaction, the chief executive officer directly owned 324,879 shares of the company’s stock, valued at approximately $28,761,537.87. The trade was a 8.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 126,953 shares of company stock worth $12,612,264 in the last 90 days. 5.02% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Nuvalent

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Nuvalent by 20.0% in the 1st quarter. Bank of America Corp DE now owns 216,516 shares of the company’s stock worth $22,182,000 after purchasing an additional 36,147 shares in the last quarter. Tri Locum Partners LP increased its holdings in Nuvalent by 0.4% in the 1st quarter. Tri Locum Partners LP now owns 308,506 shares of the company’s stock worth $31,606,000 after purchasing an additional 1,135 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Nuvalent by 141.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after buying an additional 195 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Nuvalent by 29.7% in the 1st quarter. California State Teachers Retirement System now owns 49,670 shares of the company’s stock valued at $5,089,000 after buying an additional 11,386 shares during the last quarter. Finally, Royal Bank of Canada grew its position in shares of Nuvalent by 1,537.9% in the 1st quarter. Royal Bank of Canada now owns 23,569 shares of the company’s stock valued at $2,414,000 after buying an additional 22,130 shares during the last quarter. Institutional investors and hedge funds own 97.26% of the company’s stock.

More Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s $10.6 billion all-cash acquisition offer gives Nuvalent shareholders a clear exit value at $124.00 per share, which is the biggest reason the stock has increased. Reuters article on GSK deal
• Positive Sentiment: Market commentary says the deal makes strategic sense for GSK because Nuvalent adds a late-stage oncology pipeline, supporting confidence that the transaction is credible and financially meaningful. MarketBeat analysis of the acquisition
• Neutral Sentiment: Several shareholder law firms have launched investigations into whether the sale process and price are fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Neutral Sentiment: Analyst downgrades followed the takeover news, but their revised price targets remain close to the deal value, so these moves are unlikely to outweigh the acquisition catalyst. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, a modest negative sentiment signal that may reinforce the view that insiders have been reducing exposure ahead of the transaction. SEC insider filing

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.